About Ovarian Cancer
Ovarian cancer is the fifth leading cause of cancer-related death among women in the United States and affects approximately 1% of the female population. While many patients initially respond well to existing treatments—including surgery, chemotherapy, and targeted therapies—more than half experience disease recurrence. Over time, these recurrent tumors often develop resistance to standard therapies, making them significantly more difficult to treat. This high rate of relapse and resistance highlights a critical need for new therapeutic approaches that can improve long-term outcomes for patients with ovarian cancer.
BET Inhibitors and Ovarian Cancer
ZEN-3694 modulates a unique set of genes in both tumor and immune cells that may allow it – in combination with approved therapies – to treat ovarian cancers that are resistant to first-line therapies. Pre-clinically, BET inhibition with ZEN-3694 has shown to enhance anti-tumor immunity by synergizing with PD1 inhibitors in solid tumor models.
Three National Cancer Institute sponsored trials (NCT04840589, NCT05950464, NCT05327010), and one investigator-initiated trial are evaluating ZEN-3694 in combination with other agents for recurrent ovarian cancer patients.
